In a significant development in the field of medical diagnostics, Invenio Imaging has received the US Food and Drug Administration's (FDA) Breakthrough Device Designation for its innovative AI tool, the NIO Lung Cancer Reveal. This state-of-the-art imaging module is designed to support physicians in the real-time evaluation of bronchoscopic lung biopsy samples, specifically aiding in the detection of potential cancer indicators during medical procedures.
The NIO Lung Cancer Reveal module works by analysing images captured using the NIO Laser Imaging System, employing artificial intelligence to highlight cell and tissue morphologies that may signal the presence of cancer. This technology is particularly beneficial for situations where rapid on-site evaluation (ROSE) is not available. ROSE is typically recommended by bronchoscopy guidelines to ascertain whether an adequate tissue sample has been collected for further biomarker analysis and treatment planning. However, due to its limited availability, Invenio's AI module can play a crucial supplementary role in ensuring effective tissue sampling.
It is important to note that the outputs provided by the NIO Lung Cancer Reveal are not intended to serve as standalone diagnostic conclusions but rather as a supportive tool. Physicians are advised to incorporate these findings alongside other clinical evaluations to reach a comprehensive diagnosis.
Steve Pastore, MD, who serves as the vice president of clinical affairs at Invenio Imaging, expressed enthusiasm about the FDA's decision, highlighting the importance of enhancing access to on-site evaluation technologies in bronchoscopic procedures. This breakthrough designation by the FDA is a strategic move to facilitate the rapid development and regulatory review of medical devices that have the potential to offer more effective treatment or diagnosis options for life-threatening conditions, such as lung cancer.
Lung cancer remains the leading cause of cancer-related mortality in the United States, and advancements in early detection and diagnosis are crucial. Despite significant progress in bronchoscopic lung biopsy techniques, challenges in acquiring sufficient tissue for analysis persist. Invenio's NIO Lung Cancer Reveal aims to address this gap, providing an advanced tool to improve diagnostic accuracy and patient outcomes in lung cancer care.
The breakthrough device designation is part of the FDA's effort to expedite the availability of transformative medical products to healthcare providers and patients, ensuring quick access to innovative treatments and diagnostic tools for critical health conditions. This move underscores the recognised potential of Invenio Imaging’s NIO Lung Cancer Reveal to significantly impact the field of oncology diagnostics.
Source: Noah Wire Services